Aflibercept Brand Name– EYLEA
What is Aflibercept
Aflibercept is a recombinant fusion protein. It binds vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PIGF) and thereby inhibits the binding and activation of these receptors.
The drug is approved to treat neovascular (wet) age-related macular degeneration (AMD), macular edema following central retinal vein occlusion (RVO), diabetic macular edema (DME), and diabetic retinopathy.
Aflibercept is administered via intravitreal injection by a qualified physician. Avoid use of the drug in patients with ocular or periocular infections and patients with active intraocular inflammation.
Indications
- choroidal neovascularization (CNV)
- diabetic macular edema
- diabetic retinopathy
- macular degeneration
- macular edema following retinal vein occlusion
For the treatment of neovascular (wet) age-related macular degeneration (AMD)
Side Effects
- anaphylactoid reactions
- antibody formation
- blepharedema
- blurred vision
- cataracts
- conjunctival hyperemia
- corneal edema
- corneal erosion
- endophthalmitis
- foreign body sensation
- injection site reaction
- lacrimation
- myocardial infarction
- ocular hemorrhage
- ocular hypertension
- ocular infection
- ocular inflammation
- ocular pain
- photophobia
- pruritus
- rash
- retinal detachment
- stroke
- thromboembolism
- urticaria
Monitoring Parameters
- intraocular pressure
Contraindications
- breast-feeding
- children
- contraception requirements
- driving or operating machinery
- glaucoma
- increased intraocular pressure
- infants
- infertility
- inflammation
- neonates
- ocular infection
- ocular surgery
- pregnancy
- reproductive risk
Interactions
There are no drug interactions associated with Aflibercept products.
